Compare SUVEN LIFE with Panacea Biotech - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUVEN LIFESCIENCES vs PANACEA BIOTECH - Comparison Results

PANACEA BIOTECH 
   Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUVEN LIFESCIENCES PANACEA BIOTECH SUVEN LIFESCIENCES/
PANACEA BIOTECH
 
P/E (TTM) x 20.6 12.5 164.1% View Chart
P/BV x 4.2 3.0 138.4% View Chart
Dividend Yield % 0.5 0.0 -  

Financials

 SUVEN LIFESCIENCES   PANACEA BIOTECH
EQUITY SHARE DATA
    SUVEN LIFESCIENCES
Mar-19
PANACEA BIOTECH
Mar-18
SUVEN LIFESCIENCES/
PANACEA BIOTECH
5-Yr Chart
Click to enlarge
High Rs338364 92.8%   
Low Rs169129 131.2%   
Sales per share (Unadj.) Rs52.196.8 53.9%  
Earnings per share (Unadj.) Rs6.8-12.4 -55.0%  
Cash flow per share (Unadj.) Rs8.6-2.9 -300.5%  
Dividends per share (Unadj.) Rs1.500-  
Dividend yield (eoy) %0.60-  
Book value per share (Unadj.) Rs65.350.4 129.5%  
Shares outstanding (eoy) m127.2861.25 207.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.92.5 190.9%   
Avg P/E ratio x37.1-19.9 -186.8%  
P/CF ratio (eoy) x29.6-86.4 -34.2%  
Price / Book Value ratio x3.94.9 79.4%  
Dividend payout %22.00-   
Avg Mkt Cap Rs m32,27215,101 213.7%   
No. of employees `0001.12.5 43.8%   
Total wages/salary Rs m6611,516 43.6%   
Avg. sales/employee Rs Th6,132.22,401.9 255.3%   
Avg. wages/employee Rs Th611.1614.2 99.5%   
Avg. net profit/employee Rs Th803.5-307.9 -260.9%   
INCOME DATA
Net Sales Rs m6,6355,928 111.9%  
Other income Rs m24282 294.4%   
Total revenues Rs m6,8776,010 114.4%   
Gross profit Rs m1,604845 189.8%  
Depreciation Rs m221585 37.8%   
Interest Rs m381,006 3.7%   
Profit before tax Rs m1,587-664 -239.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m02 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m71899 728.2%   
Profit after tax Rs m869-760 -114.4%  
Gross profit margin %24.214.3 169.6%  
Effective tax rate %45.2-14.9 -304.4%   
Net profit margin %13.1-12.8 -102.2%  
BALANCE SHEET DATA
Current assets Rs m6,2325,603 111.2%   
Current liabilities Rs m1,4906,910 21.6%   
Net working cap to sales %71.5-22.0 -324.2%  
Current ratio x4.20.8 515.8%  
Inventory Days Days86206 42.0%  
Debtors Days Days8384 98.6%  
Net fixed assets Rs m4,0439,941 40.7%   
Share capital Rs m12761 207.7%   
"Free" reserves Rs m8,1833,026 270.4%   
Net worth Rs m8,3103,087 269.2%   
Long term debt Rs m185,707 0.3%   
Total assets Rs m10,38916,076 64.6%  
Interest coverage x43.10.3 12,666.1%   
Debt to equity ratio x01.8 0.1%  
Sales to assets ratio x0.60.4 173.2%   
Return on assets %8.71.5 571.1%  
Return on equity %10.5-24.6 -42.5%  
Return on capital %19.53.9 498.3%  
Exports to sales %024.0 0.0%   
Imports to sales %017.5 0.0%   
Exports (fob) Rs mNA1,424 0.0%   
Imports (cif) Rs mNA1,040 0.0%   
Fx inflow Rs m5,6221,600 351.4%   
Fx outflow Rs m1,7991,131 159.0%   
Net fx Rs m3,822469 815.7%   
CASH FLOW
From Operations Rs m3561,180 30.1%  
From Investments Rs m-279553 -50.4%  
From Financial Activity Rs m-225-1,644 13.7%  
Net Cashflow Rs m-14890 -165.2%  

Share Holding

Indian Promoters % 63.4 74.5 85.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.0 0.6 -  
FIIs % 0.0 1.3 -  
ADR/GDR % 0.0 0.0 -  
Free float % 36.5 23.6 154.7%  
Shareholders   37,287 10,259 363.5%  
Pledged promoter(s) holding % 0.0 35.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUVEN LIFESCIENCES With:   SUN PHARMA  DR. REDDYS LAB  GSK PHARMA  FULFORD INDIA  PROCTER & GAMBLE HEALTH  

Compare SUVEN LIFESCIENCES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Lower; Oil & Gas Stocks Fall after Attacks on Saudi Aramco(09:30 am)

Asian share markets are higher today as Chinese and Hong Kong shares show gains. The Shanghai Composite is flat while the Hang Seng is up 1.1%.

Related Views on News

SUVEN LIFESCIENCES Surges by 5%; BSE HEALTHCARE Index Up 0.5% (Market Updates)

Sep 16, 2019 | Updated on Sep 16, 2019

SUVEN LIFESCIENCES share price has surged by 5% and its current market price is Rs 294. The BSE HEALTHCARE is up by 0.5%. The top gainers in the BSE HEALTHCARE Index are SUVEN LIFESCIENCES (up 5.2%) and WOCKHARDT (up 7.4%). The top losers are AJANTA PHARMA and PIRAMAL ENTERPRISES (down 0.2%).

SUVEN LIFESCIENCES Announces Quarterly Results (1QFY20); Net Profit Up 47.2% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 572 m (up 47.2% YoY). Sales on the other hand came in at Rs 2 bn (up 3.8% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

SUVEN LIFESCIENCES 2018-19 Annual Report Analysis (Annual Result Update)

Jul 22, 2019 | Updated on Jul 22, 2019

Here's an analysis of the annual report of SUVEN LIFESCIENCES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUVEN LIFESCIENCES. Also includes updates on the valuation of SUVEN LIFESCIENCES.

SUVEN LIFESCIENCES Announces Quarterly Results (4QFY19); Net Profit Up 8.7% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 680 m (up 8.7% YoY). Sales on the other hand came in at Rs 3 bn (up 18.5% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

PANACEA BIOTECH 2017-18 Annual Report Analysis (Annual Result Update)

Mar 27, 2019 | Updated on Mar 27, 2019

Here's an analysis of the annual report of PANACEA BIOTECH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PANACEA BIOTECH. Also includes updates on the valuation of PANACEA BIOTECH.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Don't Buy Lakshmi Vilas Bank...Buy this Private Sector Bank with 74% Upside(The 5 Minute Wrapup)

Sep 4, 2019

Lakshmi Vilas Bank is in a vicious cycle. The stock is already down 57% in 2019. Despite this, the retail investors increased their holding.

Insider Buying Alert: Promoters Increase Stake in 8 High-Quality Smallcaps(Profit Hunter)

Sep 3, 2019

Insiders have increased their stakes in eight Hidden Treasure recommendations. Should you follow them?

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SUVEN LIFESCIENCES SHARE PRICE


Sep 16, 2019 11:29 AM

TRACK SUVEN LIFESCIENCES

  • Track your investment in SUVEN LIFESCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON SUVEN LIFESCIENCES

SUVEN LIFESCIENCES 5-YR ANALYSIS

COMPARE SUVEN LIFESCIENCES WITH

MARKET STATS